Status:
ACTIVE_NOT_RECRUITING
Integrated Molecular Profiling in Advanced Cancers Trial
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Breast Cancer
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being deve...
Detailed Description
The increasing appreciation and identification of specific somatic mutations and other genetic aberrations that drive cancers leave us on the threshold of a new era of "personalized cancer medicine", ...
Eligibility Criteria
Inclusion
- Patients with histological confirmation of advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas who are candidates for systemic therapy, as well as patients who are phase I trial candidates.
- Patient must be ≥ 18 years old.
- Patient's ECOG performance status equal to 0 or 1.
- All patients must have signed and dated an informed consent form.
- All patients must have sufficient archived tumor tissue for molecular profiling.
Exclusion
- None
Key Trial Info
Start Date :
February 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2027
Estimated Enrollment :
3026 Patients enrolled
Trial Details
Trial ID
NCT01505400
Start Date
February 1 2012
End Date
January 1 2027
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9